Medios AG (LON:0QB4)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 227.22M -29.5% |
| Revenue (ttm) | 1.86B +9.9% |
| Net Income | 9.63M -40.6% |
| EPS | 0.39 -38.7% |
| Shares Out | n/a |
| PE Ratio | 23.59 |
| Forward PE | 8.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Open | 10.72 |
| Previous Close | 10.80 |
| Day's Range | 10.68 - 10.74 |
| 52-Week Range | 10.68 - 17.44 |
| Beta | 1.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of ... [Read more]
Financial Performance
In 2025, Medios AG's revenue was 2.08 billion, an increase of 10.40% compared to the previous year's 1.88 billion. Earnings were 15.37 million, an increase of 22.45%.
Financial numbers in EUR Financial StatementsNews
EQS-PVR: Medios AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Medios AG Medios AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 13.08.202...
EQS-DD: Medios AG: Stefan Bauerreis, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.08.2026 / 10:00 CET/CEST The issuer is solely responsi...
Medios AG Earnings Call Transcript: Q2 2026
Revenue grew 8.4% to €1,075 million in H1 2026, with all segments contributing, but EBITDA pre fell 5.1% due to margin pressure and higher costs. Guidance was updated: revenue raised to €2.1–2.16 billion, EBITDA pre lowered to €88–92 million. Acquisition of Caelo strengthens compounding and German market presence.
Medios AG Slides: Q2 2026
Medios AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
Medios AG Quarterly report: Q2 2026
Medios AG has published its Q2 2026 quarterly earnings report on August 12, 2026.
Medios AG Earnings release: Q2 2026
Medios AG released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
EQS-Adhoc: Medios AG – Acquisition of a Majority Stake in Caesar & Loretz GmbH (Caelo) and Entry into the German Market for Active Pharmaceutical Ingredients and Excipients
EQS-Ad-hoc: Medios AG / Key word(s): Mergers and Acquisitions / Purchase of parts of a company Medios AG – Acquisition of a Majority Stake in Caesar & Loretz GmbH (Caelo) and Entry into the German Mar...
Medios AG Transcript: Investor update
Revenue guidance for 2026 is revised to EUR 2.1–2.16 billion and EBITDA to EUR 88–92 million, mainly due to margin pressure in pharmaceutical supply and regulatory changes in the cannabis business. Cost optimization is underway, with margin improvements expected in patient-specific therapies and moderate international growth.
Medios AG Press release: Investor update
Medios AG issued a press release on July 29, 2026, disclosing material business information to investors.
Medios: Adjusted guidance for FY 2026
Medios AG narrows its 2026 outlook as record first-half revenues meet softer earnings, prompting cost cuts and efficiency drives across key business segments.
EQS-Adhoc: Medios AG: Adjusted guidance for the financial year 2026
EQS-Ad-hoc: Medios AG / Key word(s): Forecast / Full year Medios AG: Adjusted guidance for the financial year 2026 28-Jul-2026 / 19:40 CET/CEST Disclosure of an inside information acc. to Article 17 M...
Medios AG Earnings Call Transcript: Q1 2026
Revenue rose 8.9% to €527.6M, but EBITDA pre fell 7.9% to €21.2M due to margin pressure. Guidance for 2026 is maintained, with profitability improvements expected in H2, driven by operational excellence and cost optimization.
Medios AG Slides: Q1 2026
Medios AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Medios AG Quarterly report: Q1 2026
Medios AG has published its Q1 2026 quarterly earnings report on May 12, 2026.
Medios AG Earnings Call Transcript: Q4 2025
Revenue grew 10.4% to EUR 2.1 billion and EBITDA pre rose 17.8% to EUR 93.1 million, driven by both organic and inorganic growth. 2026 guidance targets up to 2% revenue growth and higher margins, with continued focus on profitability, cash flow, and disciplined capital allocation.
Medios AG Annual report: Q4 2025
Medios AG has published its Q4 2025 annual report on March 26, 2026.
Medios AG Slides: Q4 2025
Medios AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
Medios CFO Falk Neukirch To Step Down When Term Expires
(RTTNews) - Medios AG (ILM1.DE, MEDOF), a German specialty pharmaceutical company, on Friday said Chief Financial Officer Falk Neukirch will step down when his current term expires on April 30 at his ...
EQS-PVR: Medios AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Medios AG Medios AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 06.03.202...
EQS-DD: Medios AG: Thomas Meier, Acquisition of 13,638 shares as part of management board remuneration (own shares of the issuer).
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.02.2026 / 10:30 CET/CEST The issuer is solely responsi...
EQS-DD: Medios AG: Christoph Prusseit, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 22.01.2026 / 14:00 CET/CEST The issuer is solely responsi...
Medios Secures Rights For Bedrocan's Medicinal Cannabis In Select EU Markets
(RTTNews) - Medios AG (MEDOF, ILM1.DE), a German specialty pharmaceutical company, Monday announced its decision to enter the medicinal cannabis market. The company has secured exclusive distribution ...
EQS-News: Medios AG enters market for medicinal cannabis
EQS-News: Medios AG / Key word(s): Product Launch Medios AG enters market for medicinal cannabis 19.01.2026 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Pres...
EQS-PVR: Medios AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Medios AG Medios AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 07.01.202...
EQS-AFR: Medios AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Medios AG / Preliminary announcement on the disclosure of financial statements Medios AG: Preliminary announcement of the publication of quarterly repor...